Daniella Beckman

Daniella Beckman has deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Daniella oversees finance, investor relations, and business development. Prior to joining Tango, she was a consultant to early-stage biotechnology companies, leading financial activities and building companies’ financial infrastructures. She also served as Interim Chief Financial Officer for Neon Therapeutics. Previously, Daniella was Chief Financial Officer of Idenix Pharmaceuticals, responsible for finance, investor relations, and IT until it was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec, and PricewaterhouseCoopers (PwC). Daniella received her BA in business administration and accounting from Boston University. In addition to Vor Bio, she also serves on the Board of Directors of Blueprint Medicines.